TABLE 2.

Summary of Survey Results on Mpox Knowledge, Attitudes, and Practices Among Adults Presenting for JYNNEOS Vaccination (N = 352)—District of Columbia. Auqust–October 2022

	First-Dose Visit, n (%)	Second-Dose Visit, n (%)
Recognized signs and symptoms of mpox*
Rash	246 (70)	285 (81)
Fever	226 (64)	268 (76)
Swollen lymph nodes	201 (57)	255 (72)
Fatigue	160 (45)	209 (59)
Chills	154 (44)	209 (59)
Scarring	138 (39)	165 (47)
Muscle aches	128 (36)	177 (50)
Headache	120 (34)	164 (47)
Severe pain	119 (34)	150 (43)
Sore throat	82 (23)	107 (30)
Mild pain	80 (23)	117 (33)
Cough	50 (14)	89 (25)
I don’t know	44 (12)	22 (6)
Only certain groups of people can get mpox
True	4 (1)	5 (1)
False	344 (98)	345 (98)
Missing	4 (1)	2 (1)
Protection against mpox occurs immediately after the first or second dose of vaccine
True	19 (5)	40 (11)
False	326 (93)	300 (85)
Missing	7 (2)	12 (3)
Vaccines for mpox should be available to anyone who wants one
Agree or strongly agree	293 (83)	306 (87)
Neutral	10 (3)	8 (2)
Disagree or strongly disagree	44 (12)	32 (9)
Missing	5 (1)	6 (2)
Trusted sources for accurate mpox information*
Doctor/health care provider	330 (94)	327 (93)
CDC	290 (82)	311 (88)
State/local public health	256 (73)	255 (72)
WHO	235 (67)	244 (69)
Health information websites	147 (42)	131 (37)
News media	87 (25)	95 (27)
Friends/family	41 (12)	38 (11)
Social media	17 (5)	22 (6)
Dating apps	16 (5)	19 (5)
Religious organizations	Not asked	5 (1)
Prefer not to answer	3 (1)	2 (1)
I don’t trust any of these	1 (0.3)	1 (0.3)
Other	Not asked	4 (1)†

^*Participants could select more than one answer.

^†Other answers included National Institutes of Health, academic/institutional, and DC government. WHO indicates World Health Organization.